COMBI-AD and BRIM8 Studies in Melanoma

Video

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

Related Videos
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Related Content
FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

November 29th 2023
Article

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Read More

Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

New Phase 1 Findings Show Promise of Cancer Vaccines in KRAS Mutations

New Phase 1 Findings Show Promise of Cancer Vaccines in KRAS Mutations

November 23rd 2023
Article

In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.

Read More

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

February 15th 2022
Podcast

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Listen

Olaptesed Pegol Delivers Promising Survival Data in GBM

Olaptesed Pegol Delivers Promising Survival Data in GBM

November 21st 2023
Article

The combination of olaptesed pegol, bevacizumab, and radiotherapy showed an improvement in overall survival among patients with glioblastoma, according to findings from a phase 1/2 study.

Read More

Johnson Analyzes Combination Immunotherapy in the First Line in Advanced Melanoma

Johnson Analyzes Combination Immunotherapy in the First Line in Advanced Melanoma

November 15th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas B. Johnson, MD, MSCI, reviewed data for safety and efficacy of immune checkpoint inhibition in patients with metastatic melanoma.

Read More